Cargando…
COVACTA trial raises questions about tocilizumab's benefit in COVID-19
Autor principal: | Furlow, Bryant |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480990/ https://www.ncbi.nlm.nih.gov/pubmed/32929415 http://dx.doi.org/10.1016/S2665-9913(20)30313-1 |
Ejemplares similares
-
Studies Raise Questions about Pavement Sealers
por: Weinhold, Bob
Publicado: (2012) -
Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)
por: Rosas, Ivan O., et al.
Publicado: (2022) -
Immunocompromised patients in the USA and UK should receive third dose of COVID-19 vaccine
por: Furlow, Bryant
Publicado: (2021) -
PFCs and Early Menopause: Association Raises Questions about Causality
por: Konkel, Lindsey
Publicado: (2014) -
Human LAT mutation results in immune deficiency and autoimmunity but also raises questions about signaling pathways
por: Weiss, Arthur
Publicado: (2016)